Top Growth Stocks for December 2025: Where to Deploy Capital Now

Forget waiting for the Fed's next move—real growth is happening in assets that don't ask for permission. While traditional finance debates rate cuts, a parallel market is minting millionaires.

The Digital Gold Rush 2.0

Bitcoin isn't just back; it's rebuilt. Institutional custody solutions have turned volatility from a bug into a feature for traders. The halving cycle narrative has shifted from speculative chatter to a core portfolio strategy for hedge funds you've actually heard of.

Ethereum's Layer-2 Takeover

Gas fees? A problem of the past. A thriving ecosystem of scaling solutions has turned Ethereum into a throughput powerhouse. The real action isn't on the mainnet—it's on the rollups and app-chains where developers are building the next billion-user applications, sidestepping traditional app store gatekeepers entirely.

The DeFi Yield Engine

Why settle for a 5% savings account when decentralized protocols automate strategies that hunt for triple-digit APY across fragmented liquidity pools? Smart contracts don't sleep, don't take holidays, and—crucially—don't charge management fees for underperformance. It's algorithmic asset management that actually works.

Regulation as a Catalyst

Clear frameworks from forward-thinking jurisdictions have done more for institutional adoption than any bull run. Blue-chip firms aren't just dipping a toe anymore; they're building dedicated digital asset desks. The narrative flipped from 'if' to 'how much.'

The cynical take? Wall Street spent a decade dismissing this space, only to now scramble and rebrand their old, fee-heavy products as 'blockchain-enabled.' Don't buy the wrapper; buy the underlying protocol that makes their new marketing possible.

Bottom line: The growth isn't in a stock ticker. It's in the foundational layers of the new internet of value. The train hasn't left the station—it's building new tracks faster than the old guard can lay down toll booths.

TLDR

• Five growth stocks span tech (NVIDIA, Amazon, Microsoft) and healthcare (CRISPR Therapeutics, Viking Therapeutics) with 18-60% annual EPS growth projections through 2030
• NVIDIA leads AI semiconductor market with 39 Strong Buy analyst ratings and 35%+ annual EPS growth forecast driven by data center and machine learning demand
• Amazon shows 25% yearly revenue growth potential from AWS cloud services, which generates over 60% of company profits, with 45 analysts giving Buy or Strong Buy ratings
• CRISPR Therapeutics advances gene therapy with Casgevy treating blood disorders and 50%+ EPS growth potential, though 35% of 17 analysts rate it Hold due to pipeline risks
• Viking Therapeutics develops VK2735 oral weight-loss drug competing in $100B+ obesity market with 60%+ projected EPS growth and 14 Strong Buy analyst ratings

Three technology companies and two healthcare firms have attracted positive analyst ratings based on their positions in artificial intelligence, cloud computing, and medical innovation markets. The stocks show projected earnings growth rates between 18% and 60% annually over the next five years.

NVIDIA Corporation

NVIDIA Corporation operates in the AI semiconductor space. The company produces graphics processing units used in data centers and machine learning applications. These chips power autonomous vehicle technology and other emerging AI systems.

NVIDIA Corporation, NVDA

Analysts project Nvidia will achieve 35% or higher annual earnings per share growth through 2030. This forecast is based on increasing adoption of AI technology across industries. Among 39 analysts covering the stock, 39 give buy ratings, one rates it hold, and one recommends selling.

The company faces occasional stock price swings related to international trade policies. However, the consensus reflects confidence in NVIDIA’s market position in AI chip manufacturing.

Amazon’s Cloud and E-Commerce Business

Amazon.com generates revenue through multiple channels including e-commerce, cloud computing, and advertising. Amazon Web Services accounts for more than 60% of the company’s profits. The cloud division is expected to grow revenue by 25% yearly through AI integration and expansion into new markets.

Amazon.com, Inc., AMZN

The company’s diverse income streams provide stability across different economic conditions. Out of 45 analysts, 47% rate Amazon a Strong Buy, 51% give it a Buy rating, and 2% rate it Hold. No analysts recommend selling the stock.

Amazon’s position in both retail and enterprise cloud services supports the bullish analyst stance. The company continues expanding its AWS services to corporate clients worldwide.

Microsoft’s Enterprise Software Position

Microsoft Corporation focuses on cloud computing through Azure and maintains a partnership with OpenAI. The company projects 18% earnings per share growth based on demand for enterprise software including Office 365. Microsoft’s connected product ecosystem creates barriers for customers considering switches to competitors.

Microsoft Corporation, MSFT

Among 33 analysts, all 33 provide buy ratings and two rate it hold. No analysts recommend selling Microsoft shares. Analysts point to untapped revenue potential from AI-powered services as a growth driver.

The company serves corporate clients with integrated software solutions. This enterprise focus provides recurring revenue streams from subscription services.

CRISPR Therapeutics Gene Therapy Development

CRISPR Therapeutics AG works in gene therapy research and development. The company’s Casgevy treatment addresses sickle cell disease and beta-thalassemia. Additional pipeline projects target cancer and diabetes treatments.

Analysts project potential earnings per share growth exceeding 50% if the company secures additional regulatory approvals. The gene therapy market could expand CRISPR’s valuation as more treatments reach patients. Of 17 analysts, 35% rate it Strong Buy, 24% give it a Buy rating, 35% rate it Hold, and 6% recommend selling.

The higher percentage of hold ratings reflects uncertainty around drug development timelines. Clinical trial outcomes and regulatory decisions affect the company’s growth trajectory.

Viking Therapeutics Weight-Loss Drug Pipeline

Viking Therapeutics Inc develops obesity treatments including the VK2735 oral therapy. Phase 2 clinical trials showed results competitive with existing GLP-1 medications like Ozempic. The global obesity treatment market exceeds $100 billion in annual sales.

Analysts project earnings per share growth above 60% based on potential partnerships and drug approvals. Fourteen analysts cover Viking, with 50% giving Strong Buy ratings, 36% rating it Buy, and 14% rating it Hold. No analysts recommend selling.

The company’s oral drug delivery method differentiates it from injectable competitors. Trial data supports the drug’s effectiveness in weight reduction compared to existing options.

Final Thoughts

All five stocks received majority buy or strong buy ratings from analysts as of December 2025. NVIDIA, Amazon, and Microsoft represent established technology companies with large market capitalizations. CRISPR Therapeutics and Viking Therapeutics are mid-cap healthcare companies with earlier-stage products.